15963092

Source:http://linkedlifedata.com/resource/pubmed/id/15963092

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0023473, umls-concept:C0030705, umls-concept:C0031327, umls-concept:C0032659, umls-concept:C0282461, umls-concept:C0939537, umls-concept:C1274040
pubmed:issue	1
pubmed:dateCreated	2005-6-20
pubmed:abstractText	This study was designed to investigate the biochemical and physiological covariates or comedications that affect the pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia (CP CML).
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/15963092-11468940, http://linkedlifedata.com/resource/pubmed/commentcorrection/15963092-1244564, http://linkedlifedata.com/resource/pubmed/commentcorrection/15963092-12637609, http://linkedlifedata.com/resource/pubmed/commentcorrection/15963092-14612892, http://linkedlifedata.com/resource/pubmed/commentcorrection/15963092-14747424, http://linkedlifedata.com/resource/pubmed/commentcorrection/15963092-14990650, http://linkedlifedata.com/resource/pubmed/commentcorrection/15963092-15255805, http://linkedlifedata.com/resource/pubmed/commentcorrection/15963092-8548747, http://linkedlifedata.com/resource/pubmed/commentcorrection/15963092-8616716, http://linkedlifedata.com/resource/pubmed/commentcorrection/15963092-8906893, http://linkedlifedata.com/resource/pubmed/commentcorrection/15963092-9131486
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7503323
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Piperazines, http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines, http://linkedlifedata.com/resource/pubmed/chemical/imatinib
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	0306-5251
pubmed:author	pubmed-author:BoltonA EAE, pubmed-author:CapdevilleRR, pubmed-author:GathmannII, pubmed-author:HensleyMM, pubmed-author:IRIS Study Group, pubmed-author:PengBB, pubmed-author:Racine-PoonAA, pubmed-author:RiviereG-JGJ, pubmed-author:SchmidliHH
pubmed:issnType	Print
pubmed:volume	60
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	35-44
pubmed:dateRevised	2009-11-18
pubmed:meshHeading	pubmed-meshheading:15963092-Adolescent, pubmed-meshheading:15963092-Adult, pubmed-meshheading:15963092-Aged, pubmed-meshheading:15963092-Antineoplastic Agents, pubmed-meshheading:15963092-Female, pubmed-meshheading:15963092-Humans, pubmed-meshheading:15963092-Leukemia, Myeloid, Chronic-Phase, pubmed-meshheading:15963092-Male, pubmed-meshheading:15963092-Middle Aged, pubmed-meshheading:15963092-Piperazines, pubmed-meshheading:15963092-Pyrimidines
pubmed:year	2005
pubmed:articleTitle	Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.
pubmed:affiliation	Novartis Pharma AG, Basel, Switzerland. heinz.schmidli@pharma.novartis.com
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase III